CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Opiant Pharmaceuticals, Inc. - OPNT CFD

Market is not available at the moment

Market information is presented
as of 2023-09-21

  • Summary
Trading Conditions
Spread 0.13
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* N/A
Open* 20.72
1-Year Change* -20.22%
Day's Range* 20.57 - 20.94
52 wk Range 7.34-29.25
Average Volume (10 days) 90.34K
Average Volume (3 months) 1.58M
Market Cap 108.80M
P/E Ratio -100.00K
Shares Outstanding 5.27M
Revenue 22.34M
EPS -6.56
Dividend (Yield %) N/A
Beta 0.82
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Date Close Change Change (%) Open High Low
Mar 1, 2023 20.60 -0.11 -0.53% 20.71 20.94 20.52
Feb 28, 2023 20.73 0.06 0.29% 20.67 20.87 20.67
Feb 27, 2023 20.73 0.06 0.29% 20.67 20.83 20.67
Feb 24, 2023 20.83 0.31 1.51% 20.52 20.94 20.52
Feb 23, 2023 20.71 -0.08 -0.38% 20.79 20.85 20.52
Feb 22, 2023 20.77 0.24 1.17% 20.53 20.99 20.52
Feb 21, 2023 20.73 -0.22 -1.05% 20.95 20.96 20.54
Feb 17, 2023 20.86 0.03 0.14% 20.83 20.92 20.74
Feb 16, 2023 20.81 -0.16 -0.76% 20.97 21.17 20.78
Feb 15, 2023 20.91 0.17 0.82% 20.74 20.97 20.74
Feb 14, 2023 20.94 0.12 0.58% 20.82 21.05 20.74
Feb 13, 2023 20.92 0.02 0.10% 20.90 20.96 20.75
Feb 10, 2023 21.06 0.23 1.10% 20.83 21.09 20.73
Feb 9, 2023 20.75 -0.23 -1.10% 20.98 21.01 20.72
Feb 8, 2023 21.07 0.33 1.59% 20.74 21.11 20.55
Feb 7, 2023 20.93 0.23 1.11% 20.70 21.03 20.54
Feb 6, 2023 20.77 0.25 1.22% 20.52 21.07 20.47
Feb 3, 2023 20.17 0.18 0.90% 19.99 20.18 19.99
Feb 2, 2023 20.07 0.08 0.40% 19.99 20.07 19.96
Feb 1, 2023 20.00 -0.13 -0.65% 20.13 20.16 19.98

Opiant Pharmaceuticals, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total revenue 47.7855 29.6252 40.5198 13.9822 11.7623
Revenue 47.7855 29.6252 40.5198 13.9822 11.7623
Total Operating Expense 42.6292 31.8662 29.5918 35.2226 10.2342
Selling/General/Admin. Expenses, Total 16.7292 16.4295 12.8087 25.2027 6.32576
Research & Development 16.8335 9.24002 9.07935 8.47882 2.48651
Operating Income 5.15631 -2.24102 10.928 -21.2404 1.52812
Interest Income (Expense), Net Non-Operating -2.12325 -0.04611 0.48783 0.09639 0.02043
Net Income Before Taxes 3.03306 -2.28713 11.4158 -21.144 1.54854
Net Income After Taxes 3.00879 -1.86145 11.5931 -21.1953 1.37938
Net Income Before Extra. Items 3.00879 -1.86145 11.5931 -21.1953 1.37938
Net Income 3.00879 -1.86145 11.5931 -21.1953 1.37938
Income Available to Common Excl. Extra. Items 3.00879 -1.86145 11.5931 -21.1953 1.37938
Income Available to Common Incl. Extra. Items 3.00879 -1.86145 11.5931 -21.1953 1.37938
Diluted Net Income 3.00879 -1.86145 11.5931 -21.1953 1.37938
Diluted Weighted Average Shares 5.92007 4.24983 5.34238 2.98534 4.39314
Diluted EPS Excluding Extraordinary Items 0.50824 -0.43801 2.17002 -7.09981 0.31398
Diluted Normalized EPS 0.50824 -0.43801 2.16801 -7.08893 0.31681
Cost of Revenue, Total 9.06643 6.19671 7.72028 1.4911 1.40801
Gross Profit 38.7191 23.4285 32.7995 12.4911 10.3543
Unusual Expense (Income) 0 -0.0165 0.04998 0.01392
Dividends per Share - Common Stock Primary Issue 0
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 4.47001 13.8002 16.3391 11.2593 6.38688
Revenue 4.47001 13.8002 16.3391 11.2593 6.38688
Cost of Revenue, Total 0.42626 2.92138 3.05887 2.10673 0.97947
Gross Profit 4.04375 10.8788 13.2802 9.15258 5.40741
Total Operating Expense 16.258 12.5262 12.3786 9.01278 8.71156
Selling/General/Admin. Expenses, Total 7.00854 4.89039 4.43836 3.75655 3.6439
Research & Development 8.82318 4.71445 4.8814 3.1495 4.08819
Operating Income -11.788 1.27401 3.96044 2.24653 -2.32468
Interest Income (Expense), Net Non-Operating -0.39986 -0.49741 -0.54335 -0.56294 -0.51956
Net Income Before Taxes -12.1878 0.7766 3.4171 1.68359 -2.84423
Net Income After Taxes -12.1878 0.75233 3.4171 1.68359 -2.84423
Net Income Before Extra. Items -12.1878 0.75233 3.4171 1.68359 -2.84423
Net Income -12.1878 0.75233 3.4171 1.68359 -2.84423
Income Available to Common Excl. Extra. Items -12.1878 0.75233 3.4171 1.68359 -2.84423
Income Available to Common Incl. Extra. Items -12.1878 0.75233 3.4171 1.68359 -2.84423
Diluted Net Income -12.1878 0.75233 3.4171 1.68359 -2.84423
Diluted Weighted Average Shares 5.01526 6.98508 6.06504 5.42783 4.28292
Diluted EPS Excluding Extraordinary Items -2.43015 0.10771 0.56341 0.31018 -0.66409
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -2.43015 0.10771 0.56341 0.31018 -0.66409
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 69.159 59.0992 39.2547 29.3706 20.7549
Cash and Short Term Investments 52.8687 48.2513 30.9805 24.6136 8.1159
Cash & Equivalents 37.854 48.2513 30.9805 24.6136 8.1159
Total Receivables, Net 13.3274 8.91098 7.21837 4.48932 11.6967
Accounts Receivable - Trade, Net 13.3274 8.91098 7.21837 4.48932 11.6967
Prepaid Expenses 2.9629 1.93684 1.05582 0.26762 0.73333
Total Assets 70.4278 60.613 40.2805 29.3863 20.7733
Property/Plant/Equipment, Total - Net 1.07767 0.44965 1.01148 0 0.00118
Property/Plant/Equipment, Total - Gross 0.00754
Accumulated Depreciation, Total -0.00635
Intangibles, Net 0.01163 0.013 0.01437 0.01575 0.01712
Total Current Liabilities 6.84556 6.42024 5.60982 9.82706 5.65719
Payable/Accrued 3.36985 2.96648 1.31677 1.13296 3.15699
Accrued Expenses 0.53894 1.19094 1.75459 1.08364 0.71349
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 2.93677 2.26283 2.53845 7.61045 1.78671
Total Liabilities 23.588 25.1208 5.86448 12.5271 7.773
Total Long Term Debt 16.0691 18.7006 0 0 0
Other Liabilities, Total 0.67335 0 0.25466 2.7 2.11581
Total Equity 46.8398 35.4922 34.416 16.8593 13.0002
Common Stock 0.00491 0.00426 0.00419 0.00385 0.00254
Additional Paid-In Capital 108.57 100.204 97.2395 91.2761 66.2231
Retained Earnings (Accumulated Deficit) -61.6803 -64.6891 -62.8276 -74.4207 -53.2253
Total Liabilities & Shareholders’ Equity 70.4278 60.613 40.2805 29.3863 20.7733
Total Common Shares Outstanding 4.90985 4.25811 4.18644 3.84536 2.53577
Other Current Assets, Total 0 0.20904
Other Long Term Assets, Total 0.17953 1.05123
Long Term Debt 16.0691 18.7006
Other Equity, Total -0.05482 -0.02693
Short Term Investments 15.0147
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 59.1599 69.159 67.8764 60.518 56.1037
Cash and Short Term Investments 50.8255 52.8687 50.3293 48.5156 48.048
Cash & Equivalents 48.3254 37.854 35.2846 33.4433 35.4496
Short Term Investments 2.50009 15.0147 15.0448 15.0723 12.5984
Total Receivables, Net 4.45339 13.3274 15.4259 9.72539 5.60902
Accounts Receivable - Trade, Net 4.45339 13.3274 15.4259 9.72539 5.60902
Prepaid Expenses 3.88101 2.9629 2.12115 2.277 2.44677
Total Assets 60.3188 70.4278 68.9797 61.7584 58.9033
Property/Plant/Equipment, Total - Net 0.94517 1.07767 1.0913 1.22806 0.28621
Intangibles, Net 0.01129 0.01163 0.01197 0.01231 0.01266
Long Term Investments 2.50068
Other Long Term Assets, Total 0.20242 0.17953 0 0
Total Current Liabilities 6.78761 6.84556 7.35227 5.78407 6.1486
Payable/Accrued 5.31865 3.36985 2.5809 2.44698 3.68024
Accrued Expenses 1.04271 0.53894 1.63469 1.23022 0.62955
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.42626 2.93677 3.13668 2.10686 1.8388
Total Liabilities 21.0556 23.588 26.9743 25.4023 24.9175
Total Long Term Debt 13.66 16.0691 18.9057 18.8373 18.7689
Long Term Debt 13.66 16.0691 18.9057 18.8373 18.7689
Total Equity 39.2632 46.8398 42.0054 36.3561 33.9857
Common Stock 0.00508 0.00491 0.00462 0.00435 0.00433
Additional Paid-In Capital 113.208 108.57 104.46 102.22 101.529
Retained Earnings (Accumulated Deficit) -73.8681 -61.6803 -62.4326 -65.8497 -67.5333
Other Equity, Total -0.08197 -0.05482 -0.02685 -0.01888 -0.01443
Total Liabilities & Shareholders’ Equity 60.3188 70.4278 68.9797 61.7584 58.9033
Total Common Shares Outstanding 5.07961 4.90985 4.61822 4.3496 4.33059
Other Liabilities, Total 0.60802 0.67335 0.71634 0.7809
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line 3.00879 -1.86145 11.5931 -21.1953 1.37938
Cash From Operating Activities 1.92649 -2.02877 4.06389 -0.52297 -3.84049
Amortization 0.00256 0.00214
Non-Cash Items 3.58334 2.78078 3.35786 6.54266 1.79359
Cash Interest Paid 1.53562 0 0
Changes in Working Capital -4.76009 -3.07178 -10.9478 14.1271 -7.0156
Cash From Investing Activities -15.0147 -0.05089 -0.30248 0
Capital Expenditures 0 -0.05089 -0.30248 0
Cash From Financing Activities 2.71894 19.3692 2.60542 17.0207 5.08383
Financing Cash Flow Items 0 -1.31594 -0.07 -0.16642 -0.20904
Issuance (Retirement) of Debt, Net 0 20 0 0
Net Change in Cash -10.3974 17.2709 6.36684 16.4977 1.24335
Cash Taxes Paid 0 0.039 0.0008 0.174 0.61923
Issuance (Retirement) of Stock, Net 2.71894 0.6851 2.67542 17.1871 5.29288
Cash From Operating Activities 0.09446 0.12368 0.06081
Foreign Exchange Effects -0.02807 -0.01864
Other Investing Cash Flow Items, Total -15.0147
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -12.1878 3.00879 2.25646 -1.16064 -2.84423
Cash From Operating Activities -2.10326 1.92649 -0.07706 -0.36345 1.7125
Cash From Operating Activities 0.0079 0.09446 0.0787 0.06295 0.03147
Non-Cash Items 2.23628 3.58334 2.68829 1.82681 0.94172
Cash Interest Paid 0.41496 1.53562 1.05151 0.58301 0.11452
Changes in Working Capital 7.84039 -4.76009 -5.10052 -1.09256 3.58353
Cash From Investing Activities 12.5147 -15.0147 -15.0448 -15.0723 -15.1088
Other Investing Cash Flow Items, Total 12.5147 -15.0147 -15.0448 -15.0723 -15.1088
Cash From Financing Activities 0.09746 2.71894 2.16206 0.61622 0.57962
Issuance (Retirement) of Stock, Net 0.09163 2.71894 2.16206 0.61622 0.57962
Foreign Exchange Effects -0.03737 -0.02807 -0.00699 0.01149 0.01489
Net Change in Cash 10.4715 -10.3974 -12.9667 -14.8081 -12.8018
Cash Taxes Paid 0 0 0
Capital Expenditures 0 0
Financing Cash Flow Items 0.00582 0
Issuance (Retirement) of Debt, Net 0

Opiant Pharmaceuticals, Inc. Company profile

About Opiant Pharmaceuticals Inc

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing medicines for addictions and drug overdose. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdose. Its lead development product include OPNT003. The Company’s pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD), and Acute Cannabinoid Overdose (ACO). The Company also is focused on other treatment opportunities within the addiction and drug overdose field.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Opiant Pharmaceuticals Inc revenues increased 61% to $47.8M. Net income totaled $3M vs. loss of $1.9M. Revenues reflect Royalty revenue increase of 49% to $40.7M, Grant and contract revenue increase from $2.2M to $7.1M. Net Income reflects Sales and marketing decrease of 2% to $4.6M (expense), Gain (loss) on foreign exchange decrease of 44% to $5K (expense).

Equity composition

Common Stock $.001 Par, 10/11, 200M auth., 91,996,333 issd. Insiders own 21.97%. 08/09, 20-for-1 stocksplit. 8/09, Name changed from Madrona Ventures, Inc. 12/14, 1-for-100 reverse stock split.

Industry: Bio Therapeutic Drugs

233 Wilshire Blvd
Suite 400
SANTA MONICA
CALIFORNIA 90401
US

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

Oil - Crude

90.14 Price
+0.770% 1D Chg, %
Long position overnight fee 0.0415%
Short position overnight fee -0.0634%
Overnight fee time 21:00 (UTC)
Spread 0.030

XRP/USD

0.52 Price
+0.700% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

US100

14,710.90 Price
+0.190% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

1,598.67 Price
+0.440% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading